Huaifu Cheng1
Ulf D. Kahlert
Wenjie Shi- 1Department of Anal-colorectal Surgery, Shengli Oilfield Central Hospital, Dongying, China
- 2Molecular and Experimental Surgery, University Clinic for General-, Visceral-, Vascular- and Trans-Plantation Surgery, Medical Faculty University Hospital Magdeburg, Otto-von Guericke University, Magdeburg, Germany
Editorial on the Research Topic
lncRNAs: application in immunotherapy, radiotherapy, and chemotherapy
Cancer is notoriously challenging due to its high invasiveness and mortality rates, making the development of effective therapeutic approaches critically important (Dermani et al., 2019). The RNA-based treatments for cancer have steadily evolved from theoretical concepts to practical applications (Burnett and Rossi, 2012). Within these therapies, non-coding RNA (ncRNA), which does not encode proteins, demonstrates clinical efficacy against tumors by inhibiting mRNA transcription and interacting with proteins to hinder their function. Long non-coding RNAs (lncRNAs), a subclass of ncRNAs, are defined as RNA molecules that are over 200 nucleotides in length (Mattick et al., 2023). An increasing number of studies have documented that lncRNAs play versatile roles in regulating gene transcription, post-transcriptional modifications, translation, and epigenetic modifications. Dysregulation or dysfunction of lncRNAs is closely associated with various diseases (Fang and Fullwood, 2016). During cancer development, lncRNAs may regulate cell proliferation, apoptosis, migration, invasion, and the maintenance of stemness (Fang and Fullwood, 2016; de Oliveira et al., 2019).
Previous studies have shown lncRNA can regulate immune cell-specific gene expression and mediate immune processes, potentially playing a crucial role in immunotherapy resistance (Wang et al., 2014; Zhou et al., 2019). In addition, some scholars identified a lncRNA, HOTAIRM1, is significantly associated with shorter survival in glioblastoma patients, contributing to tumor aggressiveness and radioresistance, making it a potential novel therapeutic target (Ahmadov et al., 2021). Moreover, lncRNA are also recognized for their roles in ovarian cancer biology, influencing responses to various chemotherapeutic agents, including platinum salts, taxanes, and poly (ADP-ribose) polymerase (PARP) inhibitors, and have the potential to serve as biomarkers and therapeutic targets to improve treatment outcomes (Wambecke et al., 2020). Considering the crucial roles of lncRNAs in cancer, therapies based on lncRNAs may offer promising new avenues for cancer treatment. This Research Topic explores novel lncRNA-based tumor therapies, mechanisms of lncRNA regulation of therapeutic sensitivity, and the construction of lncRNA regulatory networks for therapy resistance. Additionally, it includes predictive models for antitumor efficacy, as well as the identification and validation of candidate lncRNAs to forecast prognosis and treatment outcomes, offering a comprehensive overview of the potential of lncRNAs in improving cancer treatment strategies.
Chu et al. identified a module of six cuproptosis-associated lncRNAs, termed CuLncScore from The Cancer Genome Atlas Program (TCGA) sarcoma chort, which effectively predicts sarcoma prognosis and characterizes the tumor immune microenvironment (TME). These findings suggest that cuproptosis lncRNAs play a significant role in sarcoma and could inform personalized therapeutic strategies targeting cuproptosis.
Qiao et al. successfully constructed and validated a competing endogenous RNA (ceRNA) regulatory network for tamoxifen-resistant breast cancer, identifying key genes, microRNAs (miRNAs), and lncRNAs involved in drug resistance from the Gene Expression Omnibus (GEO) database. These findings provide valuable insights and potential therapeutic targets for overcoming tamoxifen resistance in breast cancer treatment.
In another study, Yin et al. identified five chemotherapy-related lncRNAs that predict drug resistance in hepatocellular carcinoma (HCC) with high accuracy, highlighting CAHM, coding cell adhesion molecule hemophilic, as a hub lncRNA for chemotherapy resistance. Molecular docking suggested Moschus as a potential candidate drug targeting CAHM, offering new therapeutic avenues for overcoming HCC drug resistance.
Yang et al. also reported a case study highlights the effectiveness of combining pembrolizumab and I-125 seeds brachytherapy (ISB) in treating mesenchymal-epithelial transition (MET) amplification advanced non-small cell lung cancer (NSCLC) resistant to MET inhibitors. Additionally, the identification of lncRNA AL654754.1 as a key factor in radiotherapy response through pathway analysis underscores its potential role in enhancing precision treatment for lung cancer.
In addition, some scholars have reviewed the roles of lncRNAs in tumors and diseases within this Research Topic, such as Hong et al. reviewed the roles and regulatory activities of lncRNAs in HCC, highlighting their involvement in various stages of HCC progression and their potential as diagnostic and therapeutic targets. Understanding these mechanisms may improve diagnostic sensitivity and specificity and lead to the development of HCC-specific treatments.
Zhang et al. highlighted the role of lncRNAs in gastric cancer (GC) immunotherapy, emphasizing their impact on treatment efficacy and drug resistance. It discussed the mechanisms by which lncRNAs regulate immune-related features and contribute to immunotherapy resistance in GC, offering insights into potential therapeutic strategies.
Ghafouri-Fard et al. summarized the diagnostic and prognostic significance of lncRNA prostate androgen-regulated transcript 1 (PART1) in multiple cancers and non-malignant disorders, including prostate cancer, intervertebral disc degeneration, and Parkinson’s disease, emphasizing the role of PART1 in cell proliferation, migration, and metastasis.
Autophagy can both suppress and promote cancer and increasing evidence shows that dysregulated lncRNA expression could disrupt autophagic balance, leading to cancer progression. Liu et al. summarized the molecular mechanisms linking lncRNAs to autophagy and their implications for cancer progression and treatment.
All these researches have shown that lncRNAs can regulate immune processes, influence drug resistance, and modulate TME, contributing to cancer progression and treatment outcomes. This compilation of studies underscores the significant roles of lncRNAs in various cancers, highlighting their potential as biomarkers and therapeutic targets. Collectively, as research on lncRNAs deepens, novel opportunities for enhancing cancer prognosis and therapeutic strategies are emerging.
Author contributions
HC: Formal Analysis, Resources, Writing–original draft, Investigation, Methodology. UK: Methodology, Software, Supervision, Validation, Visualization, Writing–review and editing. WS: Supervision, Writing–review and editing, Conceptualization, Data curation, Formal Analysis, Resources, Writing–original draft.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Ahmadov, U., Picard, D., Bartl, J., Silginer, M., Trajkovic-Arsic, M., Qin, N., et al. (2021). The long non-coding RNA Hotairm1 promotes tumor aggressiveness and radiotherapy resistance in glioblastoma. Cell death Dis. 12 (10), 885. doi:10.1038/s41419-021-04146-0
Burnett, J. C., and Rossi, J. J. (2012). RNA-based therapeutics: current progress and future prospects. Chem. Biol. 19 (1), 60–71. doi:10.1016/j.chembiol.2011.12.008
de Oliveira, J. C., Oliveira, L. C., Mathias, C., Pedroso, G. A., Lemos, D. S., Salviano-Silva, A., et al. (2019). Long non-coding RNAs in cancer: another layer of complexity. J. gene Med. 21 (1), e3065. doi:10.1002/jgm.3065
Dermani, F. K., Samadi, P., Rahmani, G., Kohlan, A. K., and Najafi, R. (2019). Pd-1/Pd-L1 immune checkpoint: potential target for cancer therapy. J. Cell. physiology 234 (2), 1313–1325. doi:10.1002/jcp.27172
Fang, Y., and Fullwood, M. J. (2016). Roles, functions, and mechanisms of long non-coding RNAs in cancer. Genomics, Proteomics Bioinforma. 14 (1), 42–54. doi:10.1016/j.gpb.2015.09.006
Mattick, J. S., Amaral, P. P., Carninci, P., Carpenter, S., Chang, H. Y., Chen, L.-L., et al. (2023). Long non-coding RNAs: definitions, functions, challenges and recommendations. Nat. Rev. Mol. Cell Biol. 24 (6), 430–447. doi:10.1038/s41580-022-00566-8
Wambecke, A., Ahmad, M., Lambert, B., Joly, F., Poulain, L., Denoyelle, C., et al. (2020). The influence of long non-coding RNAs on the response to chemotherapy in ovarian cancer. Gynecol. Oncol. 156 (3), 726–733. doi:10.1016/j.ygyno.2019.12.020
Wang, P., Xue, Y., Han, Y., Lin, L., Wu, C., Xu, S., et al. (2014). The stat3-binding long noncoding RNA lnc-dc controls human dendritic cell differentiation. Science 344 (6181), 310–313. doi:10.1126/science.1251456
Keywords: lncRNAs, immunotherapy, radiotherapy, chemotherapy, cancer
Citation: Cheng H, Kahlert UD and Shi W (2024) Editorial: lncRNAs: application in immunotherapy, radiotherapy, and chemotherapy. Front. Cell Dev. Biol. 12:1438773. doi: 10.3389/fcell.2024.1438773
Received: 26 May 2024; Accepted: 15 July 2024;
Published: 25 July 2024.
Edited and reviewed by:
Philippe P. Roux, Université de Montréal, CanadaCopyright © 2024 Cheng, Kahlert and Shi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ulf D. Kahlert, ulf.kahlert@med.ovgu.de; Wenjie Shi, wenjie.shi@med.ovgu.de